These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33829404)

  • 21. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
    Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
    Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.
    Pouillon L; Baumann C; Rousseau H; Choukour M; Andrianjafy C; Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2019 Apr; 25(5):945-954. PubMed ID: 30329067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report.
    Alhalabi M; Eddin KA; Ali F; Abbas A
    Medicine (Baltimore); 2022 Jan; 101(4):e28722. PubMed ID: 35089243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
    Panés J; Lindsay JO; Teich N; Lindgren S; Colombel JF; Cornillie F; Flynn HA; Huyck S; Stryszak P; Yao R; Philip G; Reinisch W
    J Crohns Colitis; 2019 Sep; 13(9):1148-1157. PubMed ID: 30809631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis.
    Pillet S; Jarlot C; Courault M; Del Tedesco E; Chardon R; Saint-Sardos P; Presles E; Phelip JM; Berthelot P; Pozzetto B; Roblin X
    Inflamm Bowel Dis; 2015 Jul; 21(7):1580-6. PubMed ID: 25933392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multifocal Motor Neuropathy Associated with Infliximab.
    Rowan CR; Tubridy N; Cullen G
    J Crohns Colitis; 2015 Dec; 9(12):1174-5. PubMed ID: 26223843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
    Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP
    Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis.
    Andrew RE; Lauria A; Puleo FJ; Berg A; Stewart DB
    J Surg Res; 2017 Nov; 219():18-24. PubMed ID: 29078879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.
    Bravo F; Macpherson JA; Slack E; Patuto N; Cahenzli J; McCoy KD; Macpherson AJ; Juillerat P;
    Clin Transl Gastroenterol; 2021 Feb; 12(2):e00298. PubMed ID: 33735154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis.
    Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M
    Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis.
    Rodríguez-Lago I; Sempere L; Gutiérrez A; Núñez A; Leo Carnerero E; Hinojosa E; Mora M; Cañete F; Mañosa M; Herrera C; Beltrán B; Forés A; Arjona D; Barreiro-de Acosta M; Khorrami S; Aguirre U; Ginard D; Cabriada JL
    Scand J Gastroenterol; 2019 Apr; 54(4):459-464. PubMed ID: 30982369
    [No Abstract]   [Full Text] [Related]  

  • 38. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
    Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
    Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
    [No Abstract]   [Full Text] [Related]  

  • 39. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De novo inflammatory bowel disease after pediatric kidney or liver transplant.
    Fernandes MA; Braun HJ; Evason K; Rhee S; Perito ER
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27862714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.